Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 9/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30968383 | 0.86 | DHFR (1.00) | DHFRSTING1 | |
| SCHEMBL16558263 | 0.86 | DHFR (1.00) | DHFRSTING1 | |
| SCHEMBL1619438 | 0.86 | DHFR (1.00) | DHFRSTING1 | |
| SCHEMBL18744104 | 0.86 | DHFR (0.58) | DHFRLMNASMN1; SMN2MAPTESR1 | |
| SCHEMBL8537224 | 0.81 | STING1 (0.56) | DHFRLMNASMN1; SMN2MAPTSTING1 | |
| SCHEMBL21190265 | 0.80 | DHFR (0.53) | DHFRLMNASMN1; SMN2MAPTESR1 | |
| SCHEMBL1425902 | 0.80 | DHFR (0.66) | DHFRSTING1 | |
| SCHEMBL22824300 | 0.79 | DHFR (0.49) | DHFRLMNASMN1; SMN2MAPTESR1 | |
| SCHEMBL22801254 | 0.79 | DHFR (0.48) | DHFRLMNASMN1; SMN2MAPTESR1 | |
| SCHEMBL21178039 | 0.79 | DHFR (0.48) | DHFRLMNASMN1; SMN2MAPTESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226239-A1 | POLYMERIC MICELLE COMPLEXES, FORMULATIONS, AND USES THEREOF | ARAVASC INC. (US) | 2022-07-21 | — | — | US | claimed |
| US-20220226239-A1 | POLYMERIC MICELLE COMPLEXES, FORMULATIONS, AND USES THEREOF | ARAVASC INC. (US) | 2022-07-21 | — | — | US | disclosed |
| US-20190209695-A1 | Pharmaceutical Compositions for High-Capacity Targeted Delivery | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2019-07-11 | — | — | US | disclosed |
| US-10105446-B2 | Pharmaceutical compositions for high-capacity targeted delivery | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170151240-A1 | F10 Inhibits Growth of PC3 Xenografts and Enhances the Effects of Radiation Therapy | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2017-06-01 | — | — | US | disclosed |
| US-20170080009-A1 | Oligonucleotide Compositions and Methods for Treating Acute Lymphoblastic Leukemia | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2017-03-23 | — | — | US | disclosed |
| US-20170080009-A1 | Oligonucleotide Compositions and Methods for Treating Acute Lymphoblastic Leukemia | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2017-03-23 | — | — | US | disclosed |
| US-20170014521-A1 | PHARMACEUTICAL COMPOSITIONS FOR HIGH-CAPACITY TARGETED DELIVERY | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2017-01-19 | — | — | US | disclosed |
| US-9486533-B2 | Pharmaceutical compositions for high-capacity targeted delivery | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160145619-A1 | MULTIVALENT APTAMER COMPLEXES | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2016-05-26 | — | — | US | disclosed |
| US-20130041018-A1 | METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-02-14 | — | — | US | disclosed |
| US-20110213135-A1 | Cytotoxic Nucleotides for Targeted Therapeutics | GMEINER WILLIAM H | 2011-09-01 | — | — | US | disclosed |
| US-20100261781-A1 | MULTIVALENT APTAMER COMPLEXES | GMEINER WILLIAM H | 2010-10-14 | — | — | US | disclosed |
| US-20080026947-A1 | Cytotoxic nucleotides for targeted therapeutics | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2008-01-31 | — | — | US | disclosed |
| US-6342485-B1 | ANTITUMOR AGENTS WITH NUCLEIC ACIDS | GMEINER, WILLIAM H. | 2002-01-29 | — | — | US | disclosed |
| US-6342485-B1 | ANTITUMOR AGENTS WITH NUCLEIC ACIDS | GMEINER, WILLIAM H. | 2002-01-29 | — | — | US | disclosed |
| US-5741900-A | REACTING PROTECTED FLUOROURIDINE WITH SUCCINIC ANHYDRIDE, ATTACHING TO LONG-CHAIN ALKYLAMINE CONTROLLED PORE GLASS IN ANHYDROUS PYRIDINE IN PRESENCE OF DIMETHYLAMINOPYRIDINE AND DIMETHYLAMINOPROPYL/ETHYLCARBODIIMIDE | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1998-04-21 | — | — | US | disclosed |
| US-5663321-A | INHIBITOR OF THYMIDYLATE SYNTHASE; ANTICANCER/ANTITUMOR AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-09-02 | — | — | US | disclosed |
| US-5614505-A | 5-FLUOROURIDINE OR 5-FLUORODEOXYURIDINE, DRUG DELIVERY, IMPROVED BIOAVAILABILITY, ANTICARCINOGENIC AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-03-25 | — | — | US | disclosed |
| US-5457187-A | Antitumor, anticarcinogeic agents | BOARD OF REGENTS UNIVERSITY OF NEBRASKA (US) | 1995-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209695-A1 | Pharmaceutical Compositions for High-Capacity Targeted Delivery | EPHA2, CD2BP2, ADGRE5 | DHFR 113/4885LMNA 1966/4885SMN1; SMN2 1665/4885 |
| US-10105446-B2 | Pharmaceutical compositions for high-capacity targeted delivery | EPHA2, CD2BP2, ADGRE5 | DHFR 113/4885LMNA 1966/4885SMN1; SMN2 1665/4885 |
| US-20220226239-A1 | POLYMERIC MICELLE COMPLEXES, FORMULATIONS, AND USES THEREOF | PHOSPHO1, MUC1, MCL1 | DHFR 2633/4885LMNA 339/4885SMN1; SMN2 493/4885 |
| US-20170014521-A1 | PHARMACEUTICAL COMPOSITIONS FOR HIGH-CAPACITY TARGETED DELIVERY | EPHA2, CD2BP2, ADGRE5 | DHFR 113/4885LMNA 1966/4885SMN1; SMN2 1665/4885 |
| US-20130041018-A1 | METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA | MCL1, FLT3, THPO | DHFR 194/4885LMNA 3310/4885SMN1; SMN2 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.